An observational study in Sickle Cell Disease and Sickle Cell Anemia, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Children's Hospital Medical Center, Cincinnati · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 11 under way, none of them phase 3. Anemia, Sickle Cell · Children's Hospital Medical Center, Cincinnati.
Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, this one is the only one that started in 2019, is one of 9 observational ones, reaches primary completion later than 7 of the 10 other live ones, and was the 20th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →7 of the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati are open now, in 6 countries. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 11–18
Children's Hospital Medical Center, Cincinnati · Sites in United States, Ghana, Tanzania
Ages 6 mo–6 yrs
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 13–21
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6 mo+
Children's Hospital Medical Center, Cincinnati · Sites in Dominican Republic, Jamaica, Tanzania
Ages 8+
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 66 across the 21 interventional studies, 200 across the 9 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
4 of the studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07177300Children's Hospital Medical Center, CincinnatiEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) | 2026-12 |
| NCT02286154Children's Hospital Medical Center, CincinnatiTherapeutic Response Evaluation and Adherence Trial (TREAT) | 2026-12 |
| NCT05662098Children's Hospital Medical Center, CincinnatiAlternative Dosing And Prevention of Transfusions (ADAPT) | 2026-12-31 |
| NCT06171217Children's Hospital Medical Center, CincinnatiRealizing Effectiveness Across Continents With Hydroxyurea | 2027-10-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.
Hydroxyurea (hydroxycarbamide) is the primary disease-modifying therapy for individuals with sickle cell disease (SCD) and is both US FDA- and EMA-approved for SCD treatment. Decades of research have documented that hydroxyurea reduces morbidity and mortality for affected patients. Although its primary mechanism of action for SCD is the induction of fetal hemoglobin (HbF) that prevents erythrocyte sickling, hydroxyurea is also a ribonucleotide reductase inhibitor with dose-dependent cytotoxic effects. Based on laboratory data, hydroxyurea is considered to be a potential human mutagen, clastogen, teratogen, and even carcinogen. However, most of these are theoretical human risks; for example, teratogenic effects of hydroxyurea are based on in vitro cellular data and supra-pharmacological dosing of animals, with no documented abnormalities in humans. Despite the lack of in vivo human data, the package insert for hydroxyurea, sold as either Hydrea® or Droxia® (Bristol-Myers Squibb), or as Siklos® (Addmedica) lists both pregnancy and lactation as contraindications for treatment.
This contraindication label is critically important, since women with SCD frequently have high-risk pregnancies throughout gestation, with increased morbidity and mortality for both the mother and baby. Acute clinical complications for the mother occur commonly during gestation, while placental insufficiency through repeated infarctions also leads to increased fetal morbidity. Protection of the mother's health during pregnancy is therefore a high priority, which historically has been aided by judicious use of transfusions and management by a multidisciplinary healthcare team. In the current era, many women with SCD of child-bearing age are taking daily oral hydroxyurea with an excellent treatment effect, so its forced discontinuation around the time of pregnancy represents cessation of effective therapy. Abrupt withdrawal of hydroxyurea is typically deleterious and may not be justified in this setting. Numerous published case reports and small series have described the safe use of hydroxyurea as anti-neoplastic therapy during pregnancy in women with cancer; moreover, anecdotal experience of >100 pregnancies with hydroxyurea exposure did not document any teratogenicity.
Based on the importance of determining the actual risks and benefits of continuing hydroxyurea as disease-modifying therapy during pregnancy to protect both mothers and babies, and the lack of documented in vivo data, the safety of hydroxyurea during gestation and subsequent lactation was recently identified as an important knowledge gap by the NHLBI evidence-based SCD guidelines. Further data collection is needed regarding the actual effects of hydroxyurea for women with SCD during both pregnancy and while breastfeeding. Accordingly, we will conduct a multinational research project to retrospectively capture known human exposures to hydroxyurea in the setting of SCD, which have occurred during gestation and/or lactation, to elucidate the outcomes for the mothers and their babies. Those outcomes will be compared to pregnancies in these same women without hydroxyurea exposure.
Clinical and laboratory data on up to 200 women with SCD with hydroxyurea exposure during either gestation or lactation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
Other: Chart Review
Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
Other: Chart Review · Other: Survey
Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
How long pregnant women with Sickle Cell Disease (SCD) were exposed to Hydroxyurea.
Obtain data on length of time women with SCD were exposed to Hydroxyurea prior to pregnancy, during pregnancy, and after pregnancy.
Time frame: Through completion of pregnancy, an average of 2 years
Dose of hydroxyurea taken during pregnancy.
Obtain data on the dose of Hydroxyurea taken prior to conception, during and after pregnancy.
Time frame: Through completion of pregnancy, an average of 2 years
How long infants were exposed to Hydroxyurea.
Obtain data on length of time infants were exposed to Hydroxyurea during gestation and while breastfeeding.
Time frame: Through study completion, an average of 2 years
Dose of hydroxyurea exposure in infants.
Obtain data on the dose of Hydroxyurea taken by mother during gestation and while breastfeeding infant.
Time frame: Through study completion, an average of 2 years
Health outcomes of infants exposed to Hydroxyurea.
Obtain data on the health of infant after exposure to Hydroxyurea during gestation and while breastfeeding including any complications of mother's pregnancy or delivery as well as any congenital malformations or medical conditions in infancy.
Time frame: Through study completion, an average of 2 years
Pregnancy in Sickle Cell Disease (SCD).
Compare pregnancy and delivery complications in women with SCD exposed to Hydroxyurea to pregnancy and delivery complications in women with SCD without Hydroxyurea exposure.
Time frame: Start of pregnancy until June 2019
Comparative analysis of congenital malformations or medical conditions in infants
Compare the rate of congenital malformations and/or medical conditions in infants exposed to hydroxyurea during gestation and breastfeeding to the rate of these events in infants without hydroxyurea exposure, with data collected descriptively by self-report or chart review as applicable.
Time frame: Through study completion, an average of 2 years
Started Dec 2019 (actual). Primary completion is estimated for Dec 2028, 108 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →